1. Castration-resistant prostate cancer: latest evidence and therapeutic implications. (July 2014) Authors: Suzman, Daniel L.; Antonarakis, Emmanuel S. Journal: Therapeutic advances in medical oncology Issue: Volume 6:Number 4(2014:Jul.) Page Start: 167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical activity of enzalutamide versus docetaxel in men with castration‐resistant prostate cancer progressing after abiraterone. Issue 13 (22nd July 2014) Authors: Suzman, Daniel L.; Luber, Brandon; Schweizer, Michael T.; Nadal, Rosa; Antonarakis, Emmanuel S. Journal: Prostate Issue: Volume 74:Issue 13(2014) Page Start: 1278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy. (12th December 2018) Authors: Suzman, Daniel L.; Agrawal, Sundeep; Ning, Yang‐min; Maher, V. Ellen; Fernandes, Laura L.; Karuri, Stella; Tang, Shenghui; Sridhara, Rajeshwari; Schroeder, Jason; Goldberg, Kirsten B.; Ibrahim, Amna; McKee, Amy E.; Pazdur, Richard; Beaver, Julia A. Journal: Oncologist Issue: Volume 24:Number 4(2019) Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. (16th March 2016) Authors: Kazandjian, Dickran; Suzman, Daniel L.; Blumenthal, Gideon; Mushti, Sirisha; He, Kun; Libeg, Meredith; Keegan, Patricia; Pazdur, Richard Journal: Oncologist Issue: Volume 21:Number 5(2016) Page Start: 634 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non‐Small Cell Lung Cancer With Progression On or After Platinum‐Based Chemotherapy. (16th March 2016) Authors: Kazandjian, Dickran; Suzman, Daniel L.; Blumenthal, Gideon; Mushti, Sirisha; He, Kun; Libeg, Meredith; Keegan, Patricia; Pazdur, Richard Journal: Oncologist Issue: Volume 21:Number 5(2016) Page Start: 634 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. (24th April 2018) Authors: Suzman, Daniel L.; Pelosof, Lorraine; Rosenberg, Amy; Avigan, Mark I. Journal: Liver international Issue: Volume 38:Number 6(2018) Page Start: 976 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer. Issue 15 (26th August 2015) Authors: Maughan, Benjamin L.; Xhou, Xian C.; Suzman, Daniel L.; Nadal, Rosa; Bassi, Sunakshi; Schweizer, Michael T.; Antonarakis, Emmanuel S. Journal: Prostate Issue: Volume 75:Issue 15(2015) Page Start: 1814 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗